What is PellePharm?
PellePharm operates at the intersection of biotechnology and precision medicine, focusing exclusively on high-unmet-need dermatological diseases. The company's core value proposition lies in its targeted approach to treating Gorlin Syndrome, a rare genetic disorder that predisposes individuals to multiple basal cell carcinomas. By developing patidegib, a topical hedgehog pathway inhibitor, PellePharm is attempting to reduce tumor burden without the systemic side effects often associated with oral alternatives. Their market position is bolstered by strategic collaborations with patient advocacy groups like the Gorlin Syndrome Alliance, ensuring that their clinical development remains deeply aligned with patient outcomes and real-world efficacy requirements.
How much funding has PellePharm raised?
PellePharm has raised a total of $99.8M across 6 funding rounds:
Private Equity
$1.3M
Private Equity
$4.5M
Private Equity
$719K
Private Equity
$3.2M
Series B
$20M
Unspecified
$70M
Private Equity (2014): $1.3M, investors not publicly disclosed
Private Equity (2015): $4.6M, investors not publicly disclosed
Private Equity (2015): $719K, investors not publicly disclosed
Private Equity (2016): $3.2M, investors not publicly disclosed
Series B (2017): $20M backed by BridgeBio
Unspecified (2018): $70M with participation from LEO Pharma
Key Investors in PellePharm
LEO Pharma
A global, research-based pharmaceutical company specializing in medical dermatology with a century-long history of developing innovative treatments for skin conditions.
BridgeBio
A commercial-stage biopharmaceutical firm dedicated to discovering and delivering transformative medicines for patients suffering from genetic diseases and cancers.
Undisclosed Investors
What's next for PellePharm?
Looking ahead, the strategic deployment of these funds will likely focus on the successful completion of pivotal clinical studies and the subsequent preparation for commercialization. As the company transitions from a research-heavy entity to a potential commercial-stage player, the focus will shift toward scaling manufacturing capabilities and establishing robust distribution channels for its dermatological portfolio. The backing from major industry players suggests a clear path toward potential acquisition or long-term partnership models that could integrate PellePharm's proprietary technology into broader global dermatology platforms. Continued investment in clinical data integrity will remain the primary catalyst for future valuation growth and market penetration.
See full PellePharm company page
